Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies.
Costa D, Vidal A, Carrió A, Muñoz C, Arias A, Gómez C, Berneaga D, Colomer D, Rozman M, Pratcorona M, Torrebadell M, Díaz-Beyá M, Esteve J, Campo E. Costa D, et al. Among authors: torrebadell m. Acta Haematol. 2013;129(2):65-71. doi: 10.1159/000343616. Epub 2012 Nov 15. Acta Haematol. 2013. PMID: 23154527
Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
Talarn C, Urbano-Ispizua A, Martino R, Pérez-Simón JA, Batlle M, Herrera C, Granell M, Gaya A, Torrebadell M, Fernández-Avilés F, Aymerich M, Marín P, Sierra J, Montserrat E. Talarn C, et al. Among authors: torrebadell m. Haematologica. 2007 Dec;92(12):1655-63. doi: 10.3324/haematol.11076. Haematologica. 2007. PMID: 18055989 Free article.
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guàrdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Martí JM, Torrebadell M, Díaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Pratcorona M, et al. Among authors: torrebadell m. Blood. 2013 Apr 4;121(14):2734-8. doi: 10.1182/blood-2012-06-431122. Epub 2013 Feb 1. Blood. 2013. PMID: 23377436 Free article.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, Torrebadell M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordan I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan M, Delgado J. Ortíz-Maldonado V, et al. Among authors: torrebadell m. Mol Ther. 2021 Feb 3;29(2):636-644. doi: 10.1016/j.ymthe.2020.09.027. Epub 2020 Sep 20. Mol Ther. 2021. PMID: 33010231 Free PMC article. Clinical Trial.
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.
Ortiz-Maldonado V, Rives S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordan I, Villamor N, Aymerich M, Torrebadell M, Deyà À, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan M, Delgado J. Ortiz-Maldonado V, et al. Among authors: torrebadell m. J Immunother Cancer. 2021 Dec;9(12):e003644. doi: 10.1136/jitc-2021-003644. J Immunother Cancer. 2021. PMID: 34907029 Free PMC article. No abstract available.
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, Català A, Benítez-Ribas D, Giné E, Díaz-Beyá M, Correa JG, Rovira M, Montoro-Lorite M, Martínez-Roca A, Rodríguez-Lobato LG, Cabezón R, Cid J, Lozano M, Garcia-Rey E, Conde N, Pedrals G, Rozman M, Torrebadell M, Setoain X, Rodríguez S, Esteve J, Pascal M, Urbano-Ispizua Á, Juan M, Delgado J, Rives S. Ortiz-Maldonado V, et al. Among authors: torrebadell m. Am J Hematol. 2022 Jun 1;97(6):731-739. doi: 10.1002/ajh.26519. Epub 2022 Mar 11. Am J Hematol. 2022. PMID: 35253928 Free article.
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Vega-García N, Perez-Jaume S, Esperanza-Cebollada E, Vicente-Garcés C, Torrebadell M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratcorona M, Sánchez-Garcia J, García-Calderón CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Riñón Martinez-Gallo M, Muñoz L, Velasco MR, García-Morin M, Català A, Pascual A, Velasco P, Fernández JM, Lassaletta A, Fuster JL, Badell I, Molinos-Quintana Á, Molinés A, Guerra-García P, Pérez-Martínez A, García-Abós M, Robles Ortiz R, Pisa S, Adán R, Díaz de Heredia C, Dapena JL, Rives S, Ramírez-Orellana M, Camós M. Vega-García N, et al. Among authors: torrebadell m. Front Pediatr. 2021 Feb 5;8:614521. doi: 10.3389/fped.2020.614521. eCollection 2020. Front Pediatr. 2021. PMID: 33614543 Free PMC article.
35 results